Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer

Supporting evidence

• Evaluation report

• Appraisal consultation committee papers 1 (PDF 4 MB)

  Published:

  18 August 2021

• Appraisal consultation committee papers 2 (PDF 587 KB)

  Published:

  18 August 2021

• Final appraisal determination committee papers 1 (PDF 3.99 MB)

  Published:

  18 August 2021

• Final appraisal determination committee papers 2 (PDF 648 KB)

  Published:

  18 August 2021